fresolimumab

Home
Ligands
fresolimumab

GtoPdb Ligand ID: 8264

Synonyms: GC1008 | PET1073G12 [1]

Comment: Fresolimumab is a monoclonal antibody targeting all isoforms of transforming growth factor beta (TGF-β1, -β2 and -β3.).
Annotated peptide sequence information for this antibody is available from its IMGT/mAb-DB link.
BLAST peptide sequence analysis reveals patent US7723486 as the covering document for fresolimumab [1].

References
1. Ledbetter SR, Hart CP, Holgate RG, Jermutus LU, Buchanan CL, Duncan AR, Finch DK. (2010) Antibodies to TGF-[beta]. Patent number: US7723486. Assignee: Optein, Inc., Genzyme Corporation. Priority date: 08/02/2005. Publication date: 25/05/2010.
2. Lee HS, Song CY. (2010) Effects of TGF-beta on podocyte growth and disease progression in proliferative podocytopathies. Kidney Blood Press Res, 33 (1): 24-9. [PMID:20185928]
3. Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP. (2014) Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE, 9 (3): e90353. [PMID:24618589]

References

1. Ledbetter SR, Hart CP, Holgate RG, Jermutus LU, Buchanan CL, Duncan AR, Finch DK. (2010)
Antibodies to TGF-[beta].
Patent number: US7723486. Assignee: Optein, Inc., Genzyme Corporation. Priority date: 08/02/2005. Publication date: 25/05/2010.

2. Lee HS, Song CY. (2010)
Effects of TGF-beta on podocyte growth and disease progression in proliferative podocytopathies.
Kidney Blood Press Res, 33 (1): 24-9. [PMID:20185928]

3. Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP. (2014)
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.
PLoS ONE, 9 (3): e90353. [PMID:24618589]